 |
|
Rates of rare mutations soar 3 to 4 times higher in schizophrenia
March 28, 2008Multiple genetic glitches disrupt pathways critical for brain development
People with schizophrenia have high rates of rare genetic deletions and duplications that likely disrupt the developing brain, according to studies funded in part by the National Institutes of Health.
These tiny anomalies were found in 15 percent of adult onset schizophrenia patients and 20 percent of child and adolescent onset patients, compared with only 5 percent of healthy participants. Collectively, the mutations carried by patients were significantly more likely than those in healthy participants to disrupt genes involved in brain development -- potentially implicating hundreds of genes in the illness, which affects about 1 percent of adults.
"This is an important new finding in the genetics of schizophrenia," said NIMH Director Thomas R. Insel, M.D. "Identifying genes prone to harboring these mutations in brain development pathways holds promise for treatment and prevention of schizophrenia, as well as a wide range of other neurodevelopmental brain disorders."
Two independent teams of researchers report on their combined findings in an article published online in Science Express, March 27, 2008. One team was led by Judith Rapoport, M.D., and Anjene Addington, Ph.D., National Institute of Mental Health (NIMH), Intramural Research Program. The other team was led by Jonathan Sebat, Ph.D., and Shane McCarthy, Ph.D., Cold Spring Harbor Laboratory, and by Jon McClellan, Ph.D., Tom Walsh, Ph.D., and Mary-Claire King, Ph.D., University of Washington. Their research was supported in part by the NIMH, National Institute of Child Health and Human Development, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, and the National Institute on Aging.
The prevailing genetic model of schizophrenia implicates common variants of certain suspect candidate genes, each exerting modest effects, in interaction with each other and environmental factors. This hypothesis holds that risk stems from common variations in the sequence of the genetic code that result in altered protein products.
About a year ago, Sebat, King and colleagues reported evidence strengthening the case for a different kind of genetic risk. Many people with autism were found to have different, spontaneous and individually rare structural variations -- variations in the number of copies of genes. These copy number variations were scattered throughout the genome, suggesting that many different genes could be involved in autism spectrum disorders.
The new findings in schizophrenia echo those in autism, but also broaden their implications. The results suggest a new approach for discovering genes for schizophrenia and other mental disorders, say the researchers. Any mutation in the hundreds of genes involved in brain development could lead to a different set of neurodevelopmental consequences - schizophrenia, autism, mental retardation, or no illness at all. Each person with one of the illnesses could have a different genetic cause for the disorder.
The functional consequences of these structural genetic variations may differ, depending on interactions with other genes or environmental events, say the researchers, making any gene harboring a deleterious structural mutation a "candidate gene." Any gene harboring one mutation likely contains others. Although each might be individually rare, together such disease-causing variations in one gene could explain a substantial number of illness cases, they suggest.
Among key study findings:
* Genes disrupted in patients, as opposed to healthy participants, were significantly over-represented in pathways critical for brain development. These included genes involved in creating the infrastructure by which neurons communicate -- and for neuronal growth, migration, proliferation, differentiation, and cell death. Among these were genes important for neuronal communications via glutamate and neuregulin, both of which have previously been implicated in schizophrenia.
* The mutations were often specific to single cases or families. Virtually every mutation detected by King, Sebat and colleagues was different in a sample of 150 adults with schizophrenia and 268 healthy controls.
* In families affected by childhood onset schizophrenia, Rapoport and colleagues found that 28 percent (23) of 83 patients harbored mutations, compared with 13 percent (10) of 77 controls. By using the non-transmitted chromosomes of the patients' parents as controls, the researchers were able to determine if the mutations in their children were likely inherited or spontaneous. The majority turned out to be inherited rather than spontaneous, some from parents unaffected by the illness. Childhood onset schizophrenia is thought to be a more severe and more genetically influenced form of the illness.
NIH/National Institute of Mental Health
"This is an important new finding in the genetics of schizophrenia," said NIMH Director Thomas R. Insel, M.D. "Identifying genes prone to harboring these mutations in brain development pathways holds promise for treatment and prevention of schizophrenia, as well as a wide range of other neurodevelopmental brain disorders."
Two independent teams of researchers report on their combined findings in an article published online in Science Express, March 27, 2008. One team was led by Judith Rapoport, M.D., and Anjene Addington, Ph.D., National Institute of Mental Health (NIMH), Intramural Research Program. The other team was led by Jonathan Sebat, Ph.D., and Shane McCarthy, Ph.D., Cold Spring Harbor Laboratory, and by Jon McClellan, Ph.D., Tom Walsh, Ph.D., and Mary-Claire King, Ph.D., University of Washington. Their research was supported in part by the NIMH, National Institute of Child Health and Human Development, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, and the National Institute on Aging.
The prevailing genetic model of schizophrenia implicates common variants of certain suspect candidate genes, each exerting modest effects, in interaction with each other and environmental factors. This hypothesis holds that risk stems from common variations in the sequence of the genetic code that result in altered protein products.
About a year ago, Sebat, King and colleagues reported evidence strengthening the case for a different kind of genetic risk. Many people with autism were found to have different, spontaneous and individually rare structural variations -- variations in the number of copies of genes. These copy number variations were scattered throughout the genome, suggesting that many different genes could be involved in autism spectrum disorders.
The new findings in schizophrenia echo those in autism, but also broaden their implications. The results suggest a new approach for discovering genes for schizophrenia and other mental disorders, say the researchers. Any mutation in the hundreds of genes involved in brain development could lead to a different set of neurodevelopmental consequences - schizophrenia, autism, mental retardation, or no illness at all. Each person with one of the illnesses could have a different genetic cause for the disorder.
The functional consequences of these structural genetic variations may differ, depending on interactions with other genes or environmental events, say the researchers, making any gene harboring a deleterious structural mutation a "candidate gene." Any gene harboring one mutation likely contains others. Although each might be individually rare, together such disease-causing variations in one gene could explain a substantial number of illness cases, they suggest.
Among key study findings:
* Genes disrupted in patients, as opposed to healthy participants, were significantly over-represented in pathways critical for brain development. These included genes involved in creating the infrastructure by which neurons communicate -- and for neuronal growth, migration, proliferation, differentiation, and cell death. Among these were genes important for neuronal communications via glutamate and neuregulin, both of which have previously been implicated in schizophrenia.
* The mutations were often specific to single cases or families. Virtually every mutation detected by King, Sebat and colleagues was different in a sample of 150 adults with schizophrenia and 268 healthy controls.
* In families affected by childhood onset schizophrenia, Rapoport and colleagues found that 28 percent (23) of 83 patients harbored mutations, compared with 13 percent (10) of 77 controls. By using the non-transmitted chromosomes of the patients' parents as controls, the researchers were able to determine if the mutations in their children were likely inherited or spontaneous. The majority turned out to be inherited rather than spontaneous, some from parents unaffected by the illness. Childhood onset schizophrenia is thought to be a more severe and more genetically influenced form of the illness.
NIH/National Institute of Mental Health
Schizophrenia News and Current Schizophrenia Events RSSAnti-psychotic drug use in the elderly increases despite drug safety warnings
Three regulatory warnings of serious adverse events slowed the growth of use of atypical antipsychotic drugs among elderly patients with dementia, but they did not reduce the overall prescription rate of these drugs.
Looking beyond the drug receptor for clues to drug effectiveness
Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Severe, acute maternal stress linked to the development of schizophrenia
Pregnant women who endure the psychological stress of being in a war zone are more likely to give birth to a child who develops schizophrenia.
Unlocking mystery of why dopamine freezes Parkinson's patients
Parkinson's disease and drug addiction are polar opposite diseases, but both depend upon dopamine in the brain. Parkinson's patients don't have enough of it; drug addicts get too much of it. Although the importance of dopamine in these disorders has been well known, the way it works has been a mystery.
Human brains pay a price for being big
Metabolic changes responsible for the evolution of our unique cognitive abilities indicate that the brain may have been pushed to the limit of its capabilities. Research published today in BioMed Central's open access journal Genome Biology adds weight to the theory that schizophrenia is a costly by-product of human brain evolution.
Estrogen relieves psychotic symptoms in women with schizophrenia
When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time.
Protein marker for schizophrenia risk
A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
More Schizophrenia News Articles
 | Abnormal Psychology (5th Edition) by Thomas F. Oltmanns, Robert E. Emery This new edition retains the book's engaging and innovative systems approach, integrating the biological, psychological, and social perspectives in one concurrent story. Scientific methods are presented in a clear and non-threatening manner, and are based on the most current research. Chapter topics include personality disorders, eating disorders, substance use disorders, sexual and gender... |
 | The Soloist: A Lost Dream, an Unlikely Friendship, and the Redemptive Power of Music by Steve Lopez A moving story of the remarkable bond between a journalist in search of a story and a homeless, classically trained musician—destined to be a major motion picture from DreamWorks, starring Jamie Foxx and Robert Downey Jr.When Steve Lopez saw Nathaniel Ayers playing his heart out on a two-string violin on Los Angeles’ skid row, he found it impossible to walk away. More than thirty years earlier,... |
 | Center Cannot Hold, The: My Journey Through Madness by Elyn R. Saks Elyn Saks is a success by any measure: she's an endowed professor at the prestigious University of Southern California Gould School of Law. She has managed to achieve this in spite of being diagnosed as schizophrenic and given a "grave" prognosis -- and suffering the effects of her illness throughout her life.Saks was only eight, and living an otherwise idyllic childhood in sunny 1960s Miami,... |
 | The Quiet Room: A Journey Out of the Torment of Madness by Lori Schiller, Amanda Bennett |
 | Mad In America: Bad Science, Bad Medicine, and The Enduring Mistreatment of the Mentally Ill by Robert Whitaker Hot on the heels of an optimistic film about Nobelist John Nash's schizophrenic journey comes medical journalist Robert Whitaker's disturbing exposé of the cruel and corrupt business of treating mental illness in America. Mad in America begins by surveying three centuries of mental health treatments to discover why positive outcomes for schizophrenics in the U.S. for the last 25 years have... |
 | Surviving Schizophrenia: A Manual for Families, Consumers, and Providers (4th Edition) by E. Fuller Torrey The third edition of this indispensable manual thoroughly details everything patients, families, and mental health professionals need to know about one of the most widespread and misunderstood... |
 | Abnormal Psychology in a Changing World by Jeffrey S. Nevid, Spence A. Rathus, Beverly Greene This introduction to abnormal psychology is designed to make the material more accessible and inviting to a new generation in a changing world. Noteworthy for its clear and engaging writing style that is accessible to readers, superior pedagogy, many engaging case examples and user-oriented applications, and integration of sociocultural material throughout. The authors adopt an interactionist... |
 | Is There No Place on Earth for Me? by Susan Sheehan " A brilliantly documented chronicle of young woman's long struggle with schizophrenia."-- Willard Gaylin, The New Republic"Sylvia Frumkin," highly intelligent young girl, became a schizophrenic in her late teens and spent most of the next seventeen years in anti out of mental institutions. Susan Sheehan, a talented reporter followed "Sylvia" for almost a year talking with and observing her... |
 | Stalking Irish Madness: Searching for the Roots of My Family's Schizophrenia by Patrick Tracey In this powerful, sometimes harrowing, deeply felt story, Patrick Tracey journeys to Ireland to track the origin and solve the mystery of his Irish-American family's multigenerational struggle with schizophrenia.For most Irish Americans, a trip to Ireland is often an occasion to revisit their family's roots. But for Patrick Tracey, the lure of his ancestral home is a much more powerful need: part... |
 | A Thousand Plateaus: Capitalism and Schizophrenia by Gilles Deleuze, Felix Guattari, Brian Massumi |
| © 2008 BrightSurf.com |